Jump to content

Icosagen (company)

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by GreenC bot (talk | contribs) at 19:09, 14 November 2016 (1 archive template merged to {{webarchive}} (WAM)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Quattromed Ltd
Company typePrivately held company
IndustryBiotechnology, Biopharmaceutical industry
Founded1999
HeadquartersTartu, Estonia
Key people
Mart Ustav, CEO
ProductsProducts and services in functional genomics and proteomics, latex allergen tests
ServicesCertification: ISO 9001:2000
Websitewww.quattromed.com

Quattromed Ltd is one of the leading biotechnology companies in Estonia[1] providing medical diagnostics services and performing custom research programs for the biopharmaceutical industry. As of 2 March 2009, Icosagen AS is the new business name of the former Quattromed Ltd.

Profile

Quattromed was established in 1999 as a spin-off from Tartu University.[2] It is based in Tartu, Estonia. Employing 80 full-time employees, it has grown into the largest biotechnology company in Estonia. Quattromed started with offering molecular diagnostic services, the activities today cover molecular and clinical diagnostics (Quattromed HTI Laboratories), life science products (Quattromed), latex allergen testing (Quattromed Ltd) and protein production (Quattromed Cell Factory).

Products and services

Quattromed’s activities are divided into three branches: medical diagnostics division, technology development division and life science products division. Its main focus of activities is in gene expression and protein production. In-house proprietary technologies are used combined with extensive process know-how and partnership with academic and industrial groups. Quattromed has three patent applications in its IP portfolio, about ten technology licenses and one trade mark.

Quattromed’s main products are:

See also

References

  1. ^ Frank L. (2001). "Biotechnology in the Baltic". Nature Biotechnology. 19 (6): 513–5. doi:10.1038/89229. PMID 11385442.
  2. ^ Estonian Biotechnology Association Archived October 21, 2007, at the Wayback Machine. Retrieved 18. June 2007.
  3. ^ Kurg R; Parik J; Juronen E; Sedman T; Abroi A; Liiv I; Langel U; Ustav M. (1999). "Effect of bovine papillomavirus E2 protein-specific monoclonal antibodies on papillomavirus DNA replication". Journal of Virology. 73 (6): 4670–7. PMC 112508. PMID 10233926.
  4. ^ Kaldalu N; Lepik D; Kristjuhan A; Ustav M. (2000). "Monitoring and purification of proteins using bovine papillomavirus E2 epitope tags". Biotechniques. 28 (3): 456–60. PMID 10723557.